SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON,
D.C. 20549
___________________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported): January 25, 2011
ALBANY
MOLECULAR RESEARCH, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
000-25323
|
14-1742717
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
21
Corporate Circle, P.O. Box 15098, Albany, NY
|
12212
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (518) 512-2000
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions ( see
General Instruction A.2. below) :
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events
Albany
Molecular Research, Inc., and its exclusive licensee sanofi-aventis US filed a
stipulation regarding generic versions of Allegra-D®
24-Hour (fexofenadine HCl-pseudophedrine) tablets with the United
States District Court for the District of New Jersey on January 28, 2011.
The stipulation provides for an immediate appeal of the District Court’s Markman
ruling which was issued on January 14, 2011. The stipulation filed by AMRI and
sanofi-aventis states that based on the Court’s Markman ruling Albany and
sanofi-aventis cannot prove infringement of U.S. Patent No. 7,390,906 by Dr.
Reddy’s generic D-24 tablets. As a result of the stipulation, the District
Court has lifted the preliminary injunction prohibiting Dr. Reddy’s Laboratories
from commercializing its generic version of Allegra-D®
24-Hour (fexofenadine HCl-pseudophedrine) tablets in the United
States.
On
January 25, 2011, sanofi-aventis and its U.S. Consumer Healthcare Division,
Chattem, Inc., announced that the U.S. Food and Drug Administration (FDA)
approved the Allegra® (fexofenadine HCl) family of allergy medication products
for over-the counter (OTC) use. The Allegra® family of products will be
available in the United States without a prescription in March
2011.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
January 28, 2011
|
ALBANY
MOLECULAR RESEARCH, INC.
|
|
By:
|
/s/
Mark T. Frost
|
|
Name:
Mark T. Frost
|
||
Title:
Senior Vice President, Administration,
|
||
Chief
Financial Officer and Treasurer
|